The DOI matches its Crossref record; 95 of the 95 references it cites were found in a registry or an index.
The Biology of CD20 and Its Potential as a Target for mAb Therapy
Abstract
CD20 is a 33-37 kDa, non-glycosylated phosphoprotein expressed on the surface of almost all normal and malignant B cells. It is also the target for rituximab, the most effective anti-cancer monoclonal antibody developed to date. Rituximab has now been given to over 300,000 lymphoma patients in the last decade and interestingly is now being explored for use in other disorders, such as autoimmune conditions including rheumatoid arthritis and systemic lupus erythematosus. Despite the success in immunotherapy, knowledge about the biology of CD20 is still relatively scarce, partly because it has no known natural ligand and CD20 knockout mice display an almost normal phenotype. However, interesting insight has come from work showing that CD20 is resident in lipid raft domains of the plasma membrane where it probably functions as a store-operated calcium channel following ligation of the B cell receptor for antigen. In the current review, these and data relating to its activity as a therapeutic target will be discussed in depth. It is clear that a greater understanding of CD20 biology and the effector mechanisms, such as antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity and growth regulation, which operate with anti-CD20 mAb in vivo will allow more efficient exploitation of CD20 as a therapeutic target.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Cartron, G., Dacheux, L., Salles, G., Solal-Celigny, P., Bardos, P., Colombat, P., & Watier, H. (2002) · Blood · doi:10.1182/blood.v99.3.754 · Cited by 1,900
Weng, W.-K., & Levy, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.05.013 · Cited by 1,300
Nanoscale Organization of Multiple GPI-Anchored Proteins in Living Cell Membranes
Sharma, P., Varma, R., Sarasij, R. C., Ira, Gousset, K., Krishnamoorthy, G., Rao, M., & Mayor, S. (2004) · Cell · doi:10.1016/s0092-8674(04)00167-9 · Cited by 891
CD20: a regulator of cell-cycle progression of B lymphocytes
Tedder, T. F., & Engel, P. (1994) · Immunology Today · doi:10.1016/0167-5699(94)90276-3 · Cited by 590
Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644 · Cited by 576
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
Di Gaetano, N., Cittera, E., Nota, R., Vecchi, A., Grieco, V., Scanziani, E., Botto, M., Introna, M., & Golay, J. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1581 · Cited by 576
Anolik, J. H., Campbell, D., Felgar, R. E., Young, F., Sanz, I., Rosenblatt, J., & Looney, R. J. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10764 · Cited by 429
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
Cragg, M. S., Morgan, S. M., Chan, H. T. C., Morgan, B. P., Filatov, A. V., Johnson, P. W. M., French, R. R., & Glennie, M. J. (2003) · Blood · doi:10.1182/blood-2002-06-1761 · Cited by 390
Self-citationSignaling events involved in anti-CD20-induced apoptosis of malignant human B cells
Shan, D., Ledbetter, J. A., & Press, O. W. (2000) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050016 · Cited by 385
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
Manches, O., Lui, G., Chaperot, L., Gressin, R., Molens, J.-P., Jacob, M.-C., Sotto, J.-J., Leroux, D., Bensa, J.-C., & Plumas, J. (2003) · Blood · doi:10.1182/blood-2002-02-0469 · Cited by 372
Byrd, J. C., Kitada, S., Flinn, I. W., Aron, J. L., Pearson, M., Lucas, D., & Reed, J. C. (2002) · Blood · doi:10.1182/blood.v99.3.1038 · Cited by 367
Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas
Press, O., Appelbaum, F., Ledbetter, J., Martin, P., Zarling, J., Kidd, P., & Thomas, E. (1987) · Blood · doi:10.1182/blood.v69.2.584.584 · Cited by 361
Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents
Cragg, M. S., & Glennie, M. J. (2004) · Blood · doi:10.1182/blood-2003-06-2031 · Cited by 360
Self-citationKennedy, A. D., Beum, P. V., Solga, M. D., DiLillo, D. J., Lindorfer, M. A., Hess, C. E., Densmore, J. J., Williams, M. E., & Taylor, R. P. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.5.3280 · Cited by 359
Bubien, J. K., Zhou, L. J., Bell, P. D., Frizzell, R. A., & Tedder, T. F. (1993) · The Journal of cell biology · doi:10.1083/jcb.121.5.1121 · Cited by 355
Parren, P. W., Warmerdam, P. A., Boeije, L. C., Arts, J., Westerdaal, N. A., Vlug, A., Capel, P. J., Aarden, L. A., & van de Winkel, J. G. (1992) · Journal of Clinical Investigation · doi:10.1172/jci116022 · Cited by 346
Complement activation plays a key role in the side‐effects of rituximab treatment
Van Der Kolk, L. E., Grillo‐López, A. J., Baars, J. W., Hack, C. E., & Van Oers, M. H. J. (2001) · British Journal of Haematology · doi:10.1046/j.1365-2141.2001.03166.x · Cited by 327
Sheets, E. D., Holowka, D., & Baird, B. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.145.4.877 · Cited by 321
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
Boye, J., Elter, T., & Engert, A. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg175 · Cited by 294
Einfeld, D. A., Brown, J. P., Valentine, M. A., Clark, E. A., & Ledbetter, J. A. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb02867.x · Cited by 278
Shenoy-Scaria, A. M., Kwong, J. M. K., Fujita, T., Olszowy, M. W., Shaw, A. S., & Lublin, D. M. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.11.3535 · Cited by 276
Davis, T. A., Czerwinski, D. K., & Levy, R. (1999) · PubMed · Cited by 267
Szöllósi, J., Horejsí, V, Bene, L., Angelisová, P., & Damjanovich, S. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.7.2939 · Cited by 264
Anderson, D. R., Grillo-López, A., Varns, C., Chambers, K. S., & Hanna, N. (1997) · Biochemical Society Transactions · doi:10.1042/bst0250705 · Cited by 248
Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies.
Press, O. W., Farr, A. G., Borroz, K. I., Anderson, S. K., & Martin, P. J. (1989) · PubMed · Cited by 248
Fitzsimmons, D., Hodsdon, W., Wheat, W., Maira, S. M., Wasylyk, B., & Hagman, J. (1996) · Genes & Development · doi:10.1101/gad.10.17.2198 · Cited by 247
The mechanisms of action of rituximab in the elimination of tumor cells
Johnson, P., & Glennie, M. (2003) · Seminars in Oncology · doi:10.1053/sonc.2003.50025 · Cited by 247
Self-citationMouse CD20 expression and function
Uchida, J. (2004) · International Immunology · doi:10.1093/intimm/dxh009 · Cited by 244
Hofmeister, J. K., Cooney, D., & Coggeshall, K. M. (2000) · Blood Cells, Molecules, and Diseases · doi:10.1006/bcmd.2000.0287 · Cited by 222
Pedersen, I. M., Buhl, A. M., Klausen, P., Geisler, C. H., & Jurlander, J. (2002) · Blood · doi:10.1182/blood.v99.4.1314 · Cited by 219
Weng, W.-K., & Levy, R. (2001) · Blood · doi:10.1182/blood.v98.5.1352 · Cited by 218
Parekh, A. B. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2002.034140 · Cited by 217
Tedder, T. F., Streuli, M., Schlossman, S. F., & Saito, H. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.1.208 · Cited by 216
Chan, H. T. C., Hughes, D., French, R. R., Tutt, A. L., Walshe, C. A., Teeling, J. L., Glennie, M. J., & Cragg, M. S. (2003) · PubMed · Cited by 211
Self-citationTreon, S. P., Mitsiades, C., Mitsiades, N., Young, G., Doss, D., Schlossman, R., & Anderson, K. C. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200105000-00011 · Cited by 205
Manshouri, T., Do, K.-A., Wang, X., Giles, F. J., O'Brien, S. M., Saffer, H., Thomas, D., Jilani, I., Kantarjian, H. M., Keating, M. J., et al. (2003) · Blood · doi:10.1182/blood-2002-06-1639 · Cited by 204
Lipid raft proteins have a random distribution during localized activation of the T-cell receptor
Glebov, O. O., & Nichols, B. J. (2004) · Nature Cell Biology · doi:10.1038/ncb1103 · Cited by 200
Kansas, G. S., & Tedder, T. F. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.12.4094 · Cited by 198
Mori, Y., Wakamori, M., Miyakawa, T., Hermosura, M., Hara, Y., Nishida, M., Hirose, K., Mizushima, A., Kurosaki, M., Mori, E., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011758 · Cited by 198
Ghetie, M.-A., Bright, H., & Vitetta, E. S. (2001) · Blood · doi:10.1182/blood.v97.5.1392 · Cited by 191
M. Cardarelli, M. Q. (2002) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-001-0247-1 · Cited by 189
Golay, J. T., Clark, E. A., & Beverley, P. C. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.6.3795 · Cited by 175
Store-operated Cation Entry Mediated by CD20 in Membrane Rafts
Li, H., Ayer, L. M., Lytton, J., & Deans, J. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308802200 · Cited by 172
Retention of B-cell-specific monoclonal antibodies by human lymphoma cells
Press, O., Howell-Clark, J., Anderson, S., & Bernstein, I. (1994) · Blood · doi:10.1182/blood.v83.5.1390.1390 · Cited by 171
Polyak, M. J., & Deans, J. P. (2002) · Blood · doi:10.1182/blood.v99.9.3256 · Cited by 159
Mathas, S., Rickers, A., Bommert, K., Dörken, B., & Mapara, M. Y. (2000) · PubMed · Cited by 155
Rapid Redistribution of CD20 to a Low Density Detergent-insoluble Membrane Compartment
Deans, J. P., Robbins, S. M., Polyak, M. J., & Savage, J. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.344 · Cited by 151
Tedder, T. F., Forsgren, A., Boyd, A., Nadler, L. M., & Schlossman, S. F. (1986) · European Journal of Immunology · doi:10.1002/eji.1830160802 · Cited by 146
Liang, Y., & Tedder, T. F. (2001) · Genomics · doi:10.1006/geno.2000.6472 · Cited by 142
Selenko-Gebauer, N., Majdic, O., Draxler, S., Berer, A., Jaeger, U., Knapp, W., & Stöckl, J. (2001) · Leukemia · doi:10.1038/sj.leu.2402226 · Cited by 139
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
Jilani, I. B., O'Brien, S. M., Manshuri, T., Thomas, D. A., Thomázy, V. A., Imam, M., Naeem, S., Verstovšek, S., Kantarjian, H. M., Giles, F. J., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0055 · Cited by 136
Peripheral T-Cell Lymphoma with Aberrant Expression of CD79a and CD20: A Diagnostic Pitfall
Yao, X., Teruya‐Feldstein, J., Raffeld, M. A., Sorbara, L. R., & Jaffe, E. S. (2001) · Modern Pathology · doi:10.1038/modpathol.3880265 · Cited by 134
Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects
Rose, A. L., Smith, B. E., & Maloney, D. G. (2002) · Blood · doi:10.1182/blood.v100.5.1765.h81702001765_1765_1773 · Cited by 129
Mice carrying a CD20 gene disruption
O’Keefe, T. L., Williams, G. T., Davies, S. L., & Neuberger, M. S. (1998) · Immunogenetics · doi:10.1007/s002510050412 · Cited by 129
Pax5 Determines the Identity of B Cells from the Beginning to the End of B-lymphopoiesis
Nutt, S. L., Eberhard, D., Horcher, M., Rolink, A. G., & Busslinger, M. (2001) · International Reviews of Immunology · doi:10.3109/08830180109056723 · Cited by 126
GM1-Containing Lipid Rafts Are Depleted within Clathrin-Coated Pits
Nichols, B. J. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00209-4 · Cited by 126
Cutting Edge: B Cell Antigen Receptor Signaling Occurs Outside Lipid Rafts in Immature B Cells
Sproul, T. W., Malapati, S., Kim, J. J., & Pierce, S. K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.11.6020 · Cited by 120
Signaling antibodies in cancer therapy
Cragg, M. S., French, R. R., & Glennie, M. J. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00010-2 · Cited by 119
Self-citationPolyak, M. J., Tailor, S. H., & Deans, J. P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.7.3242 · Cited by 112
Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen
Meng-Qi, X., Hale, G., & Waldmann, H. (1993) · Molecular Immunology · doi:10.1016/0161-5890(93)90155-5 · Cited by 111
Serafini, M., Manganini, M., Borleri, G., Bonamino, M., Imberti, L., Biondi, A., Golay, J., Rambaldi, A., & Introna, M. (2004) · Human Gene Therapy · doi:10.1089/10430340460732463 · Cited by 110
Crépieux, P., Coll, J., & Stéhelin, D. (1994) · PubMed · Cited by 108
Deans, J. P., Kalt, L., Ledbetter, J. A., Schieven, G. L., Bolen, J. B., & Johnson, P. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.38.22632 · Cited by 106
Structural organization of the human MS4A gene cluster on Chromosome 11q12
Liang, Y., Buckley, T. R., Tu, L., Langdon, S. D., & Tedder, T. F. (2001) · Immunogenetics · doi:10.1007/s002510100339 · Cited by 106
Deans, J. P., Schieven, G. L., Shu, G. L., Valentine, M. A., Gilliland, L. K., Aruffo, A. A., Clark, E. A., & Ledbetter, J. A. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.9.4494 · Cited by 98
Phosphorylation of the CD20 Phosphoprotein in Resting B Lymphocytes
Valentine, M. A., Meier, K. E., Rossie, S. S., & Clark, E. A. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)60461-2 · Cited by 95
Petrie, R. J., & Deans, J. P. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.6.2886 · Cited by 93
Clark, E. A., Shu, G. L., Lüscher, B., Draves, K. E., Banchereau, J., Ledbetter, J. A., & Valentine, M. A. (1989) · The Journal of Immunology · doi:10.4049/jimmunol.143.12.3873 · Cited by 90
CD20-induced B cell death can bypass mitochondria and caspase activation
van der Kolk, L., Evers, L. M., Omene, C. O., Lens, S. M. A., Lederman, S. M., van Lier, R. A. W., van Oers, M., & Eldering, E. (2002) · Leukemia · doi:10.1038/sj.leu.2402559 · Cited by 90
Tedder, T. F., Klejman, G., Distèche, C. M., Adler, D. A., Schlossman, S. F., & Saito, H. (1988) · The Journal of Immunology · doi:10.4049/jimmunol.141.12.4388 · Cited by 85
Kanzaki, M., Shibata, H., Mogami, H., & Kojima, I. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.13099 · Cited by 85
Blakolmer, K., Vesely, M., Kummer, J. A., JURECKA, W., Mannhalter, C., & Chott, A. (2000) · Modern Pathology · doi:10.1038/modpathol.3880133 · Cited by 85
CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines
Leveillé, C., Al‐Daccak, R., & Mourad, W. M. (1999) · European Journal of Immunology · Cited by 81
Differential Effects of Filipin and Methyl-β-cyclodextrin on B Cell Receptor Signaling
Kalia, M., Schnetkamp, P. P. M., & Deans, J. P. (2001) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.5536 · Cited by 77
Venugopal, P., Sivaraman, S., Huang, X., et al. (2000) · Leukemia Research · doi:10.1016/s0145-2126(99)00206-4 · Cited by 77
Stamenkovic, I., & Seed, B. (1988) · The Journal of Experimental Medicine · doi:10.1084/jem.167.6.1975 · Cited by 71
Himmelmann, A., Riva, A., Wilson, G. L., Lucas, B. P., Thevenin, C., & Kehrl, J. H. (1997) · Blood · doi:10.1182/blood.v90.10.3984 · Cited by 68
Clark, E. A., & Shu, G. L. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.138.3.720 · Cited by 66
Thévenin, C., Lucas, B. P., Kozlow, E., & Kehrl, J. H. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53411-6 · Cited by 63
Down‐regulation of CD20 on B cells upon CD40 activation
Anolik, J. H., Looney, R. J., Bottaro, A., Sanz, I., & Young, F. M. (2003) · European Journal of Immunology · doi:10.1002/eji.200323515 · Cited by 54
Circulating CD20 and CD52 in patients with non‐Hodgkin's lymphoma or Hodgkin's disease
Giles, F. J., Vose, J. M., Do, K.-A., Johnson, M. M., Manshouri, T., Bociek, G. R., Bierman, P. J., O'Brien, S. M., Keating, M. J., Kantarjian, H. M., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04683.x · Cited by 53
A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells
Cragg, M. S., Bayne, M., Tutt, A. L., French, R. R., Beers, S. A., Glennie, M. J., & Illidge, T. (2004) · Blood · doi:10.1182/blood-2004-05-1733 · Cited by 47
Self-citationNagy, M., Chapuis, B., & Matthes, T. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03271.x · Cited by 42
The association between CD20 and Src-family Tyrosine kinases requires an additional factor
Popoff, I., Savage, J. A., Blake, J. C., Johnson, P., & Deans, J. P. (1998) · Molecular Immunology · doi:10.1016/s0161-5890(98)00042-x · Cited by 41
Vervoordeldonk, S. F., Merle, P. A., Leeuwen, E. F. V., Borne, A. E. G. K. V. D., & Slaper‐Cortenbach, I. (1994) · Cancer · Cited by 41
Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab
Dillman, R. O. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00235-5 · Cited by 38
Vaccination with CD20 peptides induces a biologically active, specific immune response in mice
Roberts, W. K., Livingston, P. O., Agus, D. B., Pinilla-Ibarz, J. A., Zelenetz, A. D., & Scheinberg, D. A. (2002) · Blood · doi:10.1182/blood.v99.10.3748 · Cited by 32
Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma
Coiffier, B. (2002) · Blood Reviews · doi:10.1016/s0268-960x(02)00059-0 · Cited by 28
Filatov, A. V., Shmigol, I. B., Kuzin, I. I., Sharonov, G. V., & Feofanov, A. V. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(03)00188-1 · Cited by 22
Apparent modulation of CD20 by rituximab: an alternative explanation
Cragg, M. S., Bayne, M. C., Illidge, T., Valerius, T., Johnson, P., & Glennie, M. J. (2004) · Blood · doi:10.1182/blood-2003-12-4384 · Cited by 22
Self-citationSerafini, M., Bonamino, M., Golay, J., & Introna, M. (2004) · PubMed · Cited by 22
Grube, M., Rezvani, K., Wiestner, A. U., Fujiwara, H., Sconocchia, G., Melenhorst, J. J., Hensel, N. F., Marti, G. E., Kwak, L. W., Wilson, W., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0075 · Cited by 21
Analysis of cis-acting elements present in the CD20/B1 antigen promoter
Rieckmann, P., Wilson, G. L., Thévenin, C., Hong, J., & Kehrl, J. H. (1991) · The Journal of Immunology · doi:10.4049/jimmunol.147.11.3994 · Cited by 18
Huang, J. S. W., Sheu, J. J., Wu, S. C. S., & Chang, T. W. (2002) · Immunology Letters · doi:10.1016/s0165-2478(01)00332-7 · Cited by 7
Cited by
Mechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515
Self-citationB-cell targeting in rheumatoid arthritis and other autoimmune diseases
Edwards, J. C. W., & Cambridge, G. (2006) · Nature Reviews Immunology · doi:10.1038/nri1838 · Cited by 507
Mitoma, H., Horiuchi, T., Tsukamoto, H., Tamimoto, Y., Kimoto, Y., Uchino, A., To, K., Harashima, S., Hatta, N., & Harada, M. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23447 · Cited by 346
Antibody therapeutics: isotype and glycoform selection
Jefferis, R. (2007) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.7.9.1401 · Cited by 294
Alduaij, W., Ivanov, A., Honeychurch, J., Cheadle, E. J., Potluri, S., Lim, S. H., Shimada, K., Chan, C. H. T., Tutt, A., Beers, S. A., et al. (2011) · Blood · doi:10.1182/blood-2010-07-296913 · Cited by 294
Self-citation
Metadata
- Authors
- Cragg, M. S., Walshe, C. A., Ivanov, A. O., & Glennie, M. J.
- Venue
- Current Directions in Autoimmunity
- Publisher
- KARGER
- Published
- 2004
- Volume
- 8
- Pages
- 140-174
- OpenAlex
- W1509374036
- Cited by
- 364
- References
- 95
- FWCI
- 73.37
- Type
- book chapter
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.